Innoheart, genae enter strategic alliance to transform translational clinical research

Innoheart and genae today announced a shared vision on integrated research services, allowing the acceleration of clinical research and development of biomedical devices and therapies. The alliance will allow both organizations to drive new growth opportunities globally and transform translational clinical research, reducing costs and accelerating market entry for new biomedical devices and therapies.

Sponsors, start-ups and academic projects with commercial potential will now be able to approach a single platform for the full development of biomedical devices from pre-clinical evaluation to late-stage clinical trials. Medical device companies and start-ups find it increasingly difficult to build such services in-house and seek partners to enable commercialization of their pipeline products. This strategic alliance allows them to address their needs on a single, global platform.

Because of the intrinsic embedment of the alliance across Europe, Asia and the US, sponsors will have multiple locations to conduct translational research.

With Innoheart's state-of-the-art imaging, pre-clinical expertise and research infrastructure in Asia combined with genae's expertise, quality and reliability, and world-class global network, the alliance will offer services that address the complete clinical research trajectory.

Collaborative objectives will include but are not limited to the expansion of services across the value chain of biomedical device R&D from pre-clinical to clinical evaluation, sharing of core lab services, particularly in relation to implantation, evaluation,disease model preparation and pivotal clinical trials.

SOURCE genae associates